{"id":828445,"date":"2025-03-21T07:04:15","date_gmt":"2025-03-21T11:04:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/"},"modified":"2025-03-21T07:04:15","modified_gmt":"2025-03-21T11:04:15","slug":"cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/","title":{"rendered":"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntal\">\n        <b><br \/>\n          <i>The Company reaffirms previously provided preliminary financial results for the quarter and full year ended <span class=\"xn-chron\">December 31, 2024<\/span>, and continues to expect regulatory decisions on DrugSorb\u2122-ATR marketing applications in 2025<\/i><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">PRINCETON, N.J.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 21, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=2504147100&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation\" target=\"_blank\" rel=\"nofollow\">CytoSorbents Corporation<\/a><\/u> (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" title=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification.  CytoSorbents\u2019 flagship product, CytoSorb\u00ae, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb\u2122-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto\/CytoSorbents Corporation)\" alt=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification.  CytoSorbents\u2019 flagship product, CytoSorb\u00ae, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb\u2122-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto\/CytoSorbents Corporation)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The Company now expects to report fourth quarter and full year 2024 financial results and file its Form 10-K after the market close on <span class=\"xn-chron\">Monday, March 31, 2025<\/span>, in compliance with applicable SEC deadlines. Management will host a live conference call, presentation webcast, and a question-and-answer session starting at <span class=\"xn-chron\">4:30PM ET<\/span> the same day.<\/p>\n<p>\n        <b>The Company continues to reiterate previously provided preliminary expectations, including: \u00a0<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Fourth quarter product revenue (excluding grant income) in the range of <span class=\"xn-money\">$9.0 million<\/span> to <span class=\"xn-money\">$9.2 million<\/span>, representing 22% to 25% growth versus <span class=\"xn-money\">$7.35 million<\/span> in the fourth quarter of 2023<\/li>\n<li>Full-year product revenue (excluding grant income) in the range of <span class=\"xn-money\">$35.4 million<\/span> to <span class=\"xn-money\">$35.6 million<\/span>, representing approximately 14% growth versus <span class=\"xn-money\">$31.1 million<\/span> for the full-year 2023<\/li>\n<li>Fourth quarter product gross margin of approximately 70%, compared to 61% in the prior quarter and 72% in the fourth quarter of 2023<\/li>\n<\/ul>\n<p>\n        <b>DrugSorb-ATR Marketing Applications<\/b>\n      <\/p>\n<p>The Company&#8217;s marketing applications for DrugSorb-ATR continue to be in substantive and interactive review with the U.S. FDA and Health Canada, and the Company continues to expect regulatory decisions from both agencies in 2025.\u00a0<\/p>\n<p>\n        <b>Estimated Pro-Forma <span class=\"xn-chron\">December 31, 2024<\/span> Cash Balance and Q4 2024 Cash Burn<\/b>\n      <\/p>\n<p>As previously disclosed, the Company has raised a total of <span class=\"xn-money\">$7.85 million<\/span> of aggregate gross proceeds in the first quarter of 2025 inclusive of <span class=\"xn-money\">$6.25 million<\/span> from the <span class=\"xn-chron\">January 10, 2025<\/span>, Rights Offering, and <span class=\"xn-money\">$1.6 million<\/span> from the related <span class=\"xn-chron\">February 24, 2025<\/span>, exercise of Series A Right Warrants.\u00a0 Proceeds net of related fees is approximately <span class=\"xn-money\">$7.3 million<\/span>. \u00a0The pro forma balance of cash, cash equivalents, and restricted cash on <span class=\"xn-chron\">December 31, 2024<\/span>, after giving effect to the Rights Offering and the exercise of Series A Right Warrants as if they had occurred on <span class=\"xn-chron\">December 31, 2024<\/span>, would have been approximately <span class=\"xn-money\">$17.0 million<\/span>, including unrestricted cash of approximately <span class=\"xn-money\">$15.5 million<\/span>. These amounts reflect <span class=\"xn-money\">$7.3 million<\/span> in net proceeds raised and net cash used in the fourth quarter of 2024 of approximately <span class=\"xn-money\">$2.5 million<\/span>. \u00a0<\/p>\n<p>The estimated financial results, proforma cash balance and estimate of cash utilized in the fourth quarter remain preliminary and unaudited.\u00a0 \u00a0<\/p>\n<p>\n        <b>Conference Call and Webcast Details:<br \/><\/b>Date: <span class=\"xn-chron\">Monday March 31, 2025<\/span><br \/>Time: <span class=\"xn-chron\">4:30 PM ET<\/span><br \/>North American toll-free: 1-800-836-8184<br \/>International toll: 1-646-357-8785<br \/>Live webcast link: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=3070335816&amp;u=https%3A%2F%2Fapp.webinar.net%2FKGyNpgaYZgQ&amp;a=https%3A%2F%2Fapp.webinar.net%2FKGyNpgaYZgQ\" target=\"_blank\" rel=\"nofollow\">https:\/\/app.webinar.net\/KGyNpgaYZgQ<\/a><\/p>\n<p>It is recommended that participants dial in approximately 10 minutes prior to the start of the call.<\/p>\n<p>An archived recording of the conference call will be available under the Investor Relations section of the Company&#8217;s website at <a href=\"https:\/\/ir.cytosorbents.com\/\" rel=\"nofollow\">https:\/\/ir.cytosorbents.com\/<\/a><\/p>\n<p>\n        <b>About CytoSorbents Corporation (NASDAQ: CTSO)<\/b>\n      <\/p>\n<p>\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=1858560066&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9JuP_ayC1LdGvZSRsWbpOcxv8qk6wGLsY2t00RIQUOzAH3VW97AvfsG_ahhmT0mys1Z7mMogHwGPt5_roawj-VjXMApe7mJPp3JTGiiEMRssOYDddfH8wccpgiHMCPcv-2cDU61vi58bwv5dHDhj7peoy1MZKZWlCXfz1_N9E3t0HjjPmVOwadc3qZ-Ve58qLcX37ZTHWslNYdMBkXhoIeyZXNyYDOo4OgcYt9s3LH6JIp5Q4wqFW8nd_3bcUoKKVTzA_KymPoJJgOppVrLNTA%3D%3D&amp;a=CytoSorbents+Corporation\" target=\"_blank\" rel=\"nofollow\">CytoSorbents Corporation<\/a>\u00a0is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents&#8217; proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.\u00a0 Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines).\u00a0 CytoSorbents&#8217; technologies are used in a number of broad applications.\u00a0 Two important ones are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis\u00a0that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.<\/p>\n<p>CytoSorbents&#8217; lead product,\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=1193282949&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9JuP_ayC1LdGvZSRsWbpORxGgG5d5RRi3BuX6LwmaJVAb04b6VxEP2rIDiYKjhRY5BGBnQuM6Q3kjTT1kfgmJGPxn9msqMZmf55jsQLSmKJgQTCQc49wvOWphERpmow-P87r7PViCzBb4Y1ZEzd5znEqmX1WUt1VTubl-o_XzoOUQxKPV1ejae2pzOWyPwo54Zr0G8HPM_KqCP8VP6Oi33ltMv4kDPIEX-iy4QoeMCsq3ZZr5KMFbJ6fBk9OngDF1tAOdFdSa6W_409-5F4-nFkP2EoLIZZPwTw-DKcZROoiFjY4tWzcmuV7qhq5LUUsQhRZ3ZAv9nDI97f4WQJ0zLoh4-r4UlAokT4cYtVx4F6tYd5dNSNSUb9Iyhc68l340zD8UOZt65d8NH0gcJyrO8V8lN3U2xWVmg3xmZPrdQM%3D&amp;a=CytoSorb\" target=\"_blank\" rel=\"nofollow\">CytoSorb<\/a><sup><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=3085032982&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DbaBPxM0OpouV4xBPdNuHYQfGlZzkY6K_qG46Q_IfgFR7arUisOobkA4cKQtSOQe-rOZwkkPdbDu0IgqPxsa3VLymjAokxa4qRMDc_fjcjL96L8-mdjI6ris1lWrtE8SBx43Dfm8nQT3BrsqC0kmhkT93ee-edDa032oIFBytvd__bccMenYfVeHvDkWY5G6WKhb_hAPt1ZDUOfDAHd_qY7W-sp6_0ILjoK7fshGy3IaCnVA6i42GWSj8gPbkimYNrkj5Qbsv4HWv0gIxibWQdHL8pgVjyUx-Eji5ostWKueYyoNF80xmsKMYMH5wRWhD2ggm8zuuzSXYU3SqdBRRB9LgsaCixpvGzMWcWwkEzfhQr32x4ogyvmWyS2yz0UfUE1F25JKP8VQFnxtCNIPX0zmBswRbttO6WNcl5IzNMKs%3D&amp;a=%C2%AE\" target=\"_blank\" rel=\"nofollow\">\u00ae<\/a><\/sup>, is approved in the\u00a0European Union\u00a0and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date.\u00a0 CytoSorb was originally launched in the\u00a0European Union\u00a0under CE mark as the first cytokine adsorber.\u00a0 Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=2928370194&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DBevZEUStHG2IGGo9anAX_kSPtnFrGz8ipiosqgiTXfKw3qMh-1zNEzD9J5E3RekPKCTE-y4C_wqlKR9OVFfNam6JivDoyEJq9TOmJbNtSM_s6u3J0KUzy0xeXAWsqydOQ92QyjhKhSinO6Gc7atcfWLADoAceyiakLu2G9QTXTlVw0OZwXiMVuyw7Cs-Ecaz0s1_fAOQaCqgeR_nCsu6Zx-7NNBmsaCYsctLsuJFh6ZJcKCFc2ZLMBH7fwvz3WQicCKLtGj29GVMBG0NasMP1FD47T7pPJz7HryVVqXdT-h7Sn515aPzGZT_cxLdRgbbvTKHF-jIiK6hN6KhFTcqs4Y-1XZADWNIKvQ7kCz-4_WrHaFKEkeE5YzTV-37oek5advSjnyuNsq6CLS3ObvS25khvux6rg-8msBJ6R6ULEUzdbyR0PTYCvqYvA8M9Y9H9dIRNnh27YgzCedTKhdDRm3tJCxmTnyRgYJ_TiUP92_ildMETnXAexElnRbsADbkpbOMOBgpXDEEuc1aySo2TEC91JyCM_BOZF3bHq5PjpP2vK1phXPmYaA8gKD6To0oPdzHfOKEEnHMLxeq_8McvrH-KoanI3LwVurLwV4IDBZm1okXjoQB81Tktr3F2hn7AlqVJsyy4wf3-OBbwxlLtN4my1RtRykA6CaYvX2b0HeDuPBOeXvrKlvOrgcUQYvUsICM9i63gvrVBV11PTn1_EgnEwV-qgj3_iEuoqsE-F8qDFpRwl4N7R4Ob8L_-ApAZrNVNIofvB5oDpym63X0Aw%3D%3D&amp;a=ticagrelor\" target=\"_blank\" rel=\"nofollow\">ticagrelor<\/a>\u00a0and\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=120644204&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dp47WrgYj8pmjYpAToXFgCBnYjnYobpTSHcu-db0NjHxVTyhpykBGcN6QCaM1R6hx33XBIndzInv4GO1RZoDg9SgJvKPmJjB6r7Kr9oCGCUVfQAWl_WP2JV8PblJXBmgLZfQk4cji55Tzbj3rMvIqVx-RNfHAwpxZPcsXWYxIbsAO4mHmlB0-RdTJDSrpZr20lyzVVmV7jh2CY7xvKtyPo6q4DNWunLrC6S5nYmqReatahfVYT6XMCCk1Y-jIv--09ysz652OrQbnfPGBOpeldNxKRA2uzZReWbvfOnn3rNsQ4QbXvXOf2DwvJWVo2JWl05tCR7JQvF87Tt00bLnfiYdmrFJegNei1CwN-G-poPHXnzp3tajndqz7lUxgs9rh8yWvU41XhRN9PyPJnkBsckHMSEDiH9uwP8g5cTQ_DPKcSwfMBo0S_Z32D0qqrdGUfE3HecdsgOanxffcpBxZOVb6_ONPyJLBB81v7of7Mcnl2U8zG4bPvikILAbdljD5dpWIvxsSk8eYN_wwAGPVwuIlEKsQDg2zUFzoWptwzTXKscjE68FBj6kM8t_9tGMCf4MoNIojWGsdX00wasx2K8c46_ig0E-RcxGAIa_ce4VQ42L_7ehyeaNlrtoZjqm5gJf1c5-UMIZ4qPtRt-GOt0-NqGzlWIesspUjNBnm9b2dZHDFzHbIYkSk_qk8BALJzyV9SiiuXog-OmC075Pgt1Qb586C-c4tf-aV9zFBey0X3bmJKxjeYES8bEziGcia7MK85FFCxPFbl7K6njmB5gHvTro8Qm3RoaxO0rsE8CaOcc3bdCFZGEJiSFPq4c-k&amp;a=rivaroxaban\" target=\"_blank\" rel=\"nofollow\">rivaroxaban<\/a>\u00a0removal in cardiothoracic surgery procedures. CytoSorb has also received\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=3033445374&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dm2FNhPcJgHNCmRfLJVv2QaAW1tb2zXDzuMyJsT4OyY05SQFzpVg7VpryNSG_1ORQ3MnpsEhyG8-uJcHJwbmf-YrAF0xdBIjMjHeE_-RbhLlxJXUYoNTG7-i2BFq6mE_3BR9lM-cyxeoPxQ8HSRVpEKZnFLf2iMp_EAjk81MLks2pp3BEPxXDg7GB8hWbWqmyEKPPOGyLg6KcQEgnq1mE-lYmkOWcZTQGWHRs7hyQeCWvm8wzHp7_-0t-GCiKaMhT76JaGuu8StI7n8bXuFfDHzO-k09EXhw5KftVKx3rGA1oeNE-oi4X3-sUrSW66jed-XUIzr5kbb6BlqcnHnShdWzbWUpSyr4Z-HGvs6H9gxx_IsW6S-XdIlg9fhtZbGNHDXyVeGym1Zgymgr16oO2XAO58RAP1-TM5pq9kjItAFFm6yDMHNv4d72c93d8jNMcSaKg2WquKvQNApj68hp_p-C69ojr1P7JX4lnHeVSFp2gJO2IdQoNBHu8TNMiQHrZXAobag-FEX0EaUdsb6S9ZJaTaZb3e4BNlN7Ae40qnjQgonSqF4K185b-ayMm3GuU02bsTFvdQZngRu65EqfK1MibhcuQXEv4-nulswtMGJsmLW7iMPrOuYHXkmZKwzn1WBMWaviYa8t9K_AvB7dkkEW7OrNN-bAhwG1tyoz695kAOwdnL0yEGS0LjB8bxDFivx-X7ZE8XzdwDP7UXuF2GonsCc1MWlwUskFiMZDFgYjg1mvJy3q3FA8V5amSK3jlJ-3DAvrirP9meVVBdXETJZ75k3u7SSgVstNgfmdVujRiw8Lx0j1Q9pnLI3nUv-BJ&amp;a=FDA+Emergency+Use+Authorization\" target=\"_blank\" rel=\"nofollow\">FDA Emergency Use Authorization<\/a>\u00a0in\u00a0the United States\u00a0for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.\u00a0 CytoSorb is not yet approved or cleared in\u00a0the\u00a0United States.<\/p>\n<p>In the U.S. and <span class=\"xn-location\">Canada<\/span>, CytoSorbents is developing the DrugSorb\u2122-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs.\u00a0 It has received two\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=1129509482&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DOVYNYVfVfZTwSB92O9_yJfhu9YsEcpW6lg6ML5vFCptxR44HDP4r6iT5zmJIIfYbxtpoGxotkZNp5WaA2UFp1BzONSEbP-JnxHDsgt_gqku1bWgZzGxpI6Bxy8IHho1GqBkd8dOKS5U2dX7yTgyMHhBD0fGGQ7lczyR_AZk-JS7x-pT_Bqfb2q2MCuc_Qt2Mgs9FkyR_XSHYG4OWBARA8nhLNtL_SvM9NL2O5rGboN8Krvuu6TNd02rb6wNKMfGErajMJbU8hamDo_tF2JVs7N27aOWiotz4FJeXcF4bPQVVdJPKLH9egCJziSVHtGjwWhwaKw1EU9j3QZ5Bj2AHo97lCl2HlB61jk9tcuabeb6hR2hJ_ugB8WUJ83E8XMXRqYvo6LvvS5HBmfJqo_vB2_yXUFwd0yCbRXiT6L0CCDpPZ1f46lUOhY7z1OhPY7_1VYEgMEZEvF7tYM08bZal17zyoqqedwkMRD4RQXmtNHMkc8_ydS4LtafjfDjtmlL6HPVYSK2x1Gt8Dm7Fv3yq4jEVuaYH2nwTMW_K7xatC6REaGB7565Mrg874XTgtGVJAWShOhSnFlTENjl80p9FSbQ54XiM9dN2w8IU9C5NAZbkXBtmLIkAcPO9EhMzW7AMp9nYsnXUBV3_iPoGb6tI-x6ytgcXVvacsFcOxZ2SGuKaRZUGawbo3Zx0R-E2rV5wkF2ckzdhToMrrBMGUNNTNfrR0geKm1pP2Sg8gDIz_SLTC6s10f6OOfVZutP_5a2dw66GfdjNZZZASjInAJRph3BAEbwo-4tb76befGMf1IDNhIXOvxRIOmULbFbaBemQ_wN52soeFXg5vuB1PCk5udsH_J8jD4brC_t_E_UNh-sSAQzUyp7x0fXOvc55-jPBVJC_KCp5TiTEpdI2j_vXLqzKS_PmazRaGRzVE9ItMAsNXP4mP4AHMf7oenhGU282VnKAcErxSOMWrkGwOhs2XjM6EU5ux5yK1n8jMGmyaSfoAQOpybL1IClQ0_e1r6zu&amp;a=FDA+Breakthrough+Device+Designations\" target=\"_blank\" rel=\"nofollow\">FDA Breakthrough Device Designations<\/a>:\u00a0 one for the removal of\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=2499683745&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DBevZEUStHG2IGGo9anAX_sK9FUmyXMo-P_MG36LpTYuG9ZUwyu7QHdXrf2ZKHbGYg4QNgsvM_gaUcmF5yklQp76iKyqOa_ddZRkBt2kRe7sC5GMbetFomKR2KWFAWOFoY5jNT4U3DHMBT9NHx4j8yO6EzDGETQTIpUmMFGySVexqa4A_PbM6jaQzEkluS4lZYntV9NN4bXRs4SPlEwUSqXroetgS_yayRqGOBHOLstwRhaFyXWcCHd4inwMm54ZE31Rmz8dBZgdcu-BRspFBE3akThhcKY0gBTYBYVSHjnCdAo5qmkv8hkWMY2G5hXVRZm2JYyraZMssywdnVF5F0CHpRAFwGEwMWE2Njj1Pt52Mo1lc3INMrhBmWDA-NmC9LEA9QwqVa46A60NbMod6s4hqQLotRCWof5KZglqdYXgC6aGeQ6hTa1ayTsYgzwiGk_tMsWUj525w4lLPPmgf3VVfvQXMrMt02b_zkMIHbZl1seiYnLx2OZZ8Dkfmzj6RtxYGZRXDgXDUE1iuVy6f0pDPoydYexYuEUvNsJ_kE99TyDpaDGuNZbtnqjCukU_X2uFDD3coXNrgGLPa-uRL3fB9B3ko7V2dTDgIZWilIpIgnatnUA-4w8Q4Dr5ZMTLqejY18puoTORponx08v437S2gIJE-PFee2zYXeJVYsfLoi5sFzFWqsrbHCHKnSJsSawGpFpdW7GT7C0rIeSwiAKlIrBE9eAQqsM-G8I70LyU6MZ2Suywae6f4rmyG6ZTAsB29xoKVR_RyrC-m4Yb8gvmrsfx4IVU0MW5MSq6lFQAX-rHR0c1yFB1abbOb3H97_ZvJC8ZJIDgiE61FVI0ehagjW7Q1rS51KqAqxNasQWSq-BaxNEeYLSrrFU552ZZD_-eKvUwlqhE7ivtmz05hiw%3D%3D&amp;a=ticagrelor\" target=\"_blank\" rel=\"nofollow\">ticagrelor<\/a>\u00a0and another for the removal of the\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=433473415&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D2qt5UxRbkefI_XwOXSqhA9q3FRJO4rv6H0__RAcvJtHWtIQeDwRE9RPGavd8-FcYqZAgy_vbeVwCWXlW4lGJ4ToTpGPq7AbbAEEKKGQFf8Pdg0EL0Dx0dn-5MH54wYgpVDUNT_RVHrdrj2dNiGCcPyOI3Lt5dUauPucTliFxodbC_ilzsO0qoWvBDY86aPH9s5HiXIvDP0Q0pcaILyeq3SvA2rhfo5M8oKbPGxwf7yajJBkQBKDyO0snrFWdLSh4fUlwEQMAIkSsYc48fSYvt21Ow3ljvmtUsSzZYqxvaEcS4qtaYXp0ztWd56XLVcLdE16GKjuBg3O9t6JeazAcWikCLHUBhbGxLKlkjaGZ-Edj0uxCOsC2fivgDUmid_d3N7IxMdopzznesT-Puyq3hZnwwG9J_UBQRWLfxuoqb1skPw5MSYR0J4izvHJkaUnuojNOdvQONtb_sIujI7A2hDFwbj0WODj7OprKHLDzNqRgw6T3MFRNWPGXTpxABWqWZ_GbEgUnF4kKfOmruUrVicFcpNWuyKrYS2a_mRDxZVjLF-VX8jmYe2mJ4n43H6ybnzFk8XeLxYBXaSzHdObYs6y9dkJ8Hwo5CrhKLznklX7DdoPvRyLY2xrnJf2dXIVyd03Wmsk0aOHffU_F8Z4fDkOjA97HQT11yVdReAcr1BwPS4pYPw2u5mKIsQlHd3OilyMVLfUQoie7mDUiLFns-CrIEoQ-mXDgoNulMDoIndvua3-dc8b6McLa5djidyYox4GWjovVTu_Beu0m0mt-6BsEFyKKURkmSdQe0uq78VtRdp9cBry4n-LRHcUz35dC-RfbEo7HL2dHS4CLnhn4KBfhCDpty6ukqhF5AbHxP9P39TM5_jbFrbNcdJ0USCdjUfwaHgzD0tali0mjBesnBtNG29aG2ikR1HPAW1fbouxtF9CsD-qhJ0KSiGRoL_avZDZI2DN3u7vn5c2NVazCMWATGVqOza8umQ_r0u4tCdv3qfrreEYDshwRLyJuIu5b7Uy1sB0dERGVHnML3KGewYgO6Sb-bpEEyL_HuQAKe17KsHeEERmwmrFKQs5iXv2IWU2u8cWQVOGEsD-4wms94t5gnUD2vt7RH1UcuyjYq9cwIpz7Y34pSY5RL_FBk69QJ4GnKifnRu8ggIK4Is_l20ecwTdmPyOQVqWcmNnu_AYYwpSRIHPT6sLK3M4BTSlnzmuTQywWbmDCJ_494lng6rZ_X_3wgSRqvhz6iRtOChA%3D&amp;a=direct+oral+anticoagulants+(DOAC)+apixaban+and+rivaroxaban\" target=\"_blank\" rel=\"nofollow\">direct oral anticoagulants (DOAC) apixaban and rivaroxaban<\/a>\u00a0in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.\u00a0 In <span class=\"xn-chron\">September 2024<\/span>, the Company <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=3334681507&amp;u=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2024%2F10%2F01%2F2955943%2F25359%2Fen%2FCytoSorbents-Submits-DrugSorb-ATR-Marketing-Application-to-U-S-FDA-to-Reduce-the-Severity-of-Bleeding-in-Heart-Bypass-Surgery-Patients-on-the-Blood-Thinner-Ticagrelor-and-Provides-.html&amp;a=submitted+a+De+Novo+medical+device+application+to+the+U.S.+FDA\" target=\"_blank\" rel=\"nofollow\">submitted a De Novo medical device application to the U.S. FDA<\/a> requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=3783182350&amp;u=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2024%2F10%2F22%2F2966804%2F25359%2Fen%2FFDA-Accepts-DrugSorb-ATR-De-Novo-Application-To-Reduce-the-Severity-of-CABG-Related-Bleeding-Due-to-Ticagrelor-and-Initiates-Substantive-Review.html&amp;a=accepted+for+substantive+review+in+October+2024\" target=\"_blank\" rel=\"nofollow\">accepted for substantive review in <span class=\"xn-chron\">October 2024<\/span><\/a>.\u00a0 In <span class=\"xn-chron\">November 2024<\/span>, the Company received its <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=2533935936&amp;u=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2024%2F11%2F04%2F2973910%2F25359%2Fen%2FCytoSorbents-Submits-Health-Canada-Medical-Device-License-Application-for-DrugSorb-ATR-Following-MDSAP-Certification.html&amp;a=Medical+Device+Single+Audit+Program+(MDSAP)+certification+and+submitted+its+Medical+Device+License+(MDL)+application+to+Health+Canada\" target=\"_blank\" rel=\"nofollow\">Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada<\/a>.\u00a0 DrugSorb-ATR is not yet granted or approved in <span class=\"xn-location\">the United States<\/span> and <span class=\"xn-location\">Canada<\/span>, respectively.<\/p>\n<p>The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued\u00a0U.S.\u00a0and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY<sup>\u00ae<\/sup>, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend\u2122-BGA, VetResQ<sup>\u00ae<\/sup>, K<sup>+<\/sup>ontrol\u2122, DrugSorb\u2122, ContrastSorb, and others. For more information, please visit the Company&#8217;s website at\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=3984152446&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D283PwmHiJUfabTqhg2ZpDnYjf5XhZAlIMyssxo2Wn0HZDSivvzAVTRU99mY8PzMEp-IQnhkHZQoIe2Y0NTRPknt-CLFn977jv46SrtQpzWNm3n0u9nL2hRtiAdAhrI0L6TWVuJ1Ua0eyYAAHFADqzuJCluIBThPOC6-_UvzALIe1NQnaWpNF96448sUkycTBYAHDVFK_bzlapHDOGsSPbzLOUlHsbY2KWL5jS7kFrD0Zxbyfj9HkBIlSZI1ISo_XSLsWMqVw9B1WeZfQjvqQRg%3D%3D&amp;a=www.cytosorbents.com\" target=\"_blank\" rel=\"nofollow\">www.cytosorbents.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=4101444332&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DsB2AG7X4Z43BoIDfgybXOhtx6hajGmLFRYdf-CJkEqF3K0BxaD2m7c_NZkYwFsYeNOY-LK22UCYVjieKWHZcgsLvVcrOalL0DfCSkqBZ2R_uGHEIFHLoP0BQqxUZI_ekbspxc47A02TOAJxuUO_K9TZyQwpeGoQum9SjiTg36Arl4PtOgWHHT25tP3a7Ym1EB8iQrlZmSYoiowd-zHbIFTmyj_pRohZ2MNAXPml_QnQFTso55cgXNSvoEGmuwOjL&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>\u00a0and\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4388471-1&amp;h=1389847178&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DKRERF9IW2qXW13jmGfo2v9T8dZnx2rVmbAIsoapwSyctLh6P5jlWX3C4X5SXqbzb0GaZHZ5_z5G5t0Zl0IzRFWQlon1TY5bfeIRgjKiElxVuahzWnjosldeOn5JOUPxhCbumHzexqM_fZKIwMl-0G9DJq4dOAR0csY-tQ8EMVLLU8LBoBFccCFGAJbSfbYFA7FgLUn1YPCc4GLWXb6T01g%3D%3D&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>.\u00a0<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management&#8217;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on <span class=\"xn-chron\">March 14, 2024<\/span>, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n<p>\n        <b>U.S. Company Contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Peter J. Mariani<\/span>, Chief Financial Officer<br \/>305 College Road East<br \/><span class=\"xn-location\">Princeton, NJ<\/span> 08540<br \/><a href=\"mailto:pmariani@cytosorbents.com\" target=\"_blank\" rel=\"nofollow\">pmariani@cytosorbents.com<\/a>\u00a0<\/p>\n<p>\n        <b>Investor Relations Contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Aman Patel<\/span>, CFA &amp; <span class=\"xn-person\">Adanna G. Alexander<\/span>, PhD<br \/>ICR Healthcare\u00a0<br \/><a href=\"mailto:ir@cytosorbents.com\" target=\"_blank\" rel=\"nofollow\">ir@cytosorbents.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY46755&amp;sd=2025-03-21\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit-302407812.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit-302407812.html<\/a><\/p>\n<p>SOURCE  Cytosorbents Corp<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY46755&amp;Transmission_Id=202503210700PR_NEWS_USPR_____NY46755&amp;DateId=20250321\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb\u2122-ATR marketing applications in 2025 PRINCETON, N.J. , March 21, 2025 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release. The Company now expects to report fourth quarter and full year 2024 financial results and file its Form 10-K after the market close on Monday, March &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828445","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb\u2122-ATR marketing applications in 2025 PRINCETON, N.J. , March 21, 2025 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release. The Company now expects to report fourth quarter and full year 2024 financial results and file its Form 10-K after the market close on Monday, March &hellip; Continue reading &quot;CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-21T11:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit\",\"datePublished\":\"2025-03-21T11:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/\"},\"wordCount\":1277,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2647016\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/\",\"name\":\"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2647016\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"datePublished\":\"2025-03-21T11:04:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2647016\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2647016\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - Market Newsdesk","og_description":"PR Newswire The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb\u2122-ATR marketing applications in 2025 PRINCETON, N.J. , March 21, 2025 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release. The Company now expects to report fourth quarter and full year 2024 financial results and file its Form 10-K after the market close on Monday, March &hellip; Continue reading \"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-21T11:04:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit","datePublished":"2025-03-21T11:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/"},"wordCount":1277,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/","name":"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","datePublished":"2025-03-21T11:04:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2647016\/CytoSorbents_Working_To_Save_Lives_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reschedules-earnings-release-to-march-31-2025-to-allow-additional-time-to-complete-annual-audit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828445"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828445\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}